Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

3,950.00p
   
  • Change Today:
      50.00p
  • 52 Week High: 4,500.00
  • 52 Week Low: 3,800.00
  • Currency: UK Pounds
  • Shares Issued: 5.21m
  • Volume: 8,977
  • Market Cap: £205.77m

Bioventix signs deal to end dispute with Diasource

By Natasha Roberts

Date: Thursday 21 Aug 2014

LONDON (ShareCast) - Bioventix, an AIM-listed company focused on the development of anti-bodies, has signed an agreement to license intellectual property owned by Belgian company Diasource ImmunoAssays.

The two groups had been in dispute over one of Diasource's European patents, but said a licence agreement was "the preferred outcome".

In April of this year, Bioventix said it was taking action to oppose the patent, which is in the field of anti-vitamin D antibodies and their use in tests for vitamin D sufficiency and deficiency.

Bioventix explained the patent is within the scope of the newly granted licence, meaning its business will no longer be potentially restricted.

The company assured investors that the licence features reasonable commercial terms and as such said it will withdraw the opposition to the European patent.

"We considered the costs of a potential dispute together with the impact of on-going uncertainty on customers and shareholders and concluded that a licence agreement with Diasource was the preferred outcome," Bioventix chief executive Peter Harrison said.

NR

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 3,950.00p
Change Today 50.00p
% Change 1.28 %
52 Week High 4,500.00
52 Week Low 3,800.00
Volume 8,977
Shares Issued 5.21m
Market Cap £205.77m

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
84.37% below the market average84.37% below the market average84.37% below the market average84.37% below the market average84.37% below the market average
72.55% below the sector average72.55% below the sector average72.55% below the sector average72.55% below the sector average72.55% below the sector average
Price Trend
63.04% below the market average63.04% below the market average63.04% below the market average63.04% below the market average63.04% below the market average
47.54% below the sector average47.54% below the sector average47.54% below the sector average47.54% below the sector average47.54% below the sector average
Income Not Available
Growth
78.01% above the market average78.01% above the market average78.01% above the market average78.01% above the market average78.01% above the market average
2.86% above the sector average2.86% above the sector average2.86% above the sector average2.86% above the sector average2.86% above the sector average

Bioventix Dividends

  Latest Previous
  1st Interim Special
Ex-Div 08-Apr-21 29-Oct-20
Paid 23-Apr-21 13-Nov-20
Amount 43.00p 53.00p

Trades for 05-Aug-2021

Time Volume / Share Price
11:42 3,000 @ 3,851.00p
11:42 3,000 @ 3,850.00p
15:39 1,250 @ 3,880.00p
16:13 99 @ 3,925.00p
16:06 50 @ 3,920.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
CFO Bruce Hiscock

Top of Page